Policy Barriers to Increasing Access to Radioligand Therapy for Neuroendocrine Cancers


Introduction: Radioligand therapy is a relatively new treatment approach used in a small number of neuroendocrine cancers and has been shown to improve overall survival and quality of life. Yet because it uses radioactivity, there are particular barriers to its greater integration into cancer care. As neuroendocrine cancers are rare, it is all the more urgent that these barriers be understood and overcome so that this treatment modality can become available to all patients who may benefit.

Aim(s): To identify existing structural, institutional and policy barriers to ensuring radioligand therapy is available to patients and use these findings to make recommendations on how key decision-makers can improve its integration into cancer care.

Materials and methods: Desk research and semi-structured interviews with nine experts from five different European countries.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Merkel C

Authors: Merkel C, Whicher C, Herrmann K, Jervis N, Ćwikła J,

Keywords: PRRT, peptide receptor radionuclide therapy, radioligand therapy, policy, multidisciplinary care, nuclear medicine, neuroendocrine cancer,

To read the full abstract, please log into your ENETS Member account.